

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIF Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/C86D817876FEN.html>

Date: August 2018

Pages: 59

Price: US\$ 3,500.00 (Single User License)

ID: C86D817876FEN

Abstracts

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIF Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H2 2018

SUMMARY

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIF Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Cell division protein kinase 7 is an enzyme that in humans is encoded by the CDK7 gene. CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. It phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation. thus regulating cell cycle progression. Upon DNA damage it triggers p53/TP53 activation by phosphorylation but is inactivated in turn by p53/TP53. This feedback loop leads to an arrest of the cell cycle.

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIF Basal Transcription Factor Complex Kinase Subunit

or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Hematological Disorders, Metabolic Disorders and Respiratory which include indications Breast Cancer, Small-Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Astrocytoma, Bleeding And Clotting Disorders, Colorectal Cancer, Cystic Fibrosis, Cytomegalovirus (HHV-5) Infections, Glioblastoma Multiforme (GBM), Gliosarcoma, Inflammation, Metastatic Hepatocellular Carcinoma (HCC), Neuroblastoma, Pancreatic Cancer, Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Rheumatoid Arthritis and Solid Tumor.

The latest report Cyclin Dependent Kinase 7 - Pipeline Review, H2 2018, outlays comprehensive information on the Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23)

The report reviews Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics and enlists all their major and minor projects

The report assesses Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) -

Overview

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) -

Companies Involved in Therapeutics Development

Aurigene Discovery Technologies Ltd

Beta Pharma Inc

Cyclacel Pharmaceuticals Inc

Qurient Co Ltd

Syros Pharmaceuticals Inc

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Drug Profiles

BS-181L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-7001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapacitabine + seliciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seliciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK7 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK7 for Small Cell Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SY-1365 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) -

Dormant Products

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIF Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Discontinued Products

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIF Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Product Development Milestones

Featured News & Press Releases

Jun 14, 2018: Lees Pharmaceutical Holdings: Update on An Investigational Oncology Product

May 16, 2018: Syros to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at Upcoming ASCO Annual Meeting

Apr 16, 2018: Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer

Apr 10, 2018: New class of drugs could help tackle treatment-resistant cancers

Mar 14, 2018: Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting

Dec 10, 2017: Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination Approach

Dec 07, 2017: Syros Presents New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, and Discovery of Potential New Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium

Nov 30, 2017: Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of its Oral CDK7 Inhibitor: CT7001

Nov 13, 2017: Syros to Present New Preclinical Data on SY-1365 and on Identification of Potential Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium

Nov 01, 2017: Syros to Present New Preclinical Data on SY-1365 At ASH Annual Meeting

Oct 30, 2017: Syros Presents New Preclinical PK and PD Data for SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference

Oct 16, 2017: Syros to Present New Preclinical PK and PD Data on SY-1365, its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference

May 15, 2017: Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors

Apr 10, 2017: Syros Announces FDA Acceptance of IND to Advance SY-1365, Its First-

in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

Apr 03, 2017: Syros Presents New Preclinical Data at AACR Showing Anti-Tumor Activity of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Multiple Difficult-to-Treat Solid Tumors

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
Pipeline by Beta Pharma Inc, H2 2018
Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018
Pipeline by Qurient Co Ltd, H2 2018
Pipeline by Syros Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

COMPANIES MENTIONED

Aurigene Discovery Technologies Ltd

Beta Pharma Inc

Cyclacel Pharmaceuticals Inc

Qurient Co Ltd

Syros Pharmaceuticals Inc

I would like to order

Product name: Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/C86D817876FEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C86D817876FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970